David Goggins
Former Navy Seal
Career Development
Bryan Cranston
Critical Thinking
Liv Boeree
International Poker Champion
Emotional Intelligence
Amaryllis Fox
Former CIA Clandestine Operative
Chris Hadfield
Retired Canadian Astronaut & Author
from the world's big
Start Learning

Researchers discover dozens of existing drugs with anti-cancer properties

Numerous drugs designed to treat diabetes, arthritis, and other conditions may actually have secret anti-cancer properties as well.

Flickr user Weining Zhong
  • A recent study identified nearly 50 different existing drugs with anti-cancer properties.
  • Learning about these previously unrecognized properties is critical — since drugs like these have already been approved for human consumption, they can be brought to the market and applied in cancer treatment faster.
  • The study also identified novel mechanisms of action that could serve as the focus of future studies.

The anti-inflammatory drug tepoxalin, primarily used for treating osteoarthritis in dogs, was recently discovered to have more uses than just helping old dogs move better. The same was found for the alcohol dependence drug disulfiram as well as vanadium, which was originally designed to treat diabetes.

Researchers discovered that these and nearly 50 other drugs developed with a variety of purposes in mind actually have previously unrecognized cancer-fighting properties. "We thought we'd be lucky if we found even a single compound with anti-cancer properties, but we were surprised to find so many," said Professor Todd Golub, co-author of a recent paper describing the work in the journal Nature Cancer.

The idea that a drug developed for one purpose can have other benefits is nothing new. Famously, one doctor's observations of his patients in 1948 led to the discovery that aspirin was not only an excellent painkiller but also helped to prevent heart attacks.

These incidental uses inspired the creation of the Broad Institute's Repurposing Hub, which contains a database of thousands of compounds approved by the Food and Drug Administration (FDA) for one use and yet may have others. The recent study was the largest to date to make use of this database.

Using cells from 578 different kinds of cancer, the researchers tested 4,518 different drugs, finding that nearly 50 had previously unrecognized cancer-fighting properties. Not only does this diversify our toolkit when treating cancer, but it also means that we can quickly bring these solutions into treatment. All the tested drugs have already been approved by the FDA for human consumption, and many are already in mass production.

Revealing new cancer-fighting capacities

In order to rapidly test the different cancer cell lines against a compound, the researchers used a method called PRISM (profiling relative inhibition simultaneously in mixtures), which consists of adding a short DNA "barcode" to the cells that enabled the researchers to test several cell lines at once. After exposing a group to a given compound, the researchers could measure the cells' survivability rates based on these barcodes.

Not only did this reveal different compounds' cancer-fighting properties, it also revealed unique mechanisms of action. "Most existing cancer drugs work by blocking proteins, but we're finding that compounds can act through other mechanisms," said study co-author Steven Corsello. For instance, nearly a dozen drugs killed cancer cells by targeting the interaction between two proteins commonly expressed in cancer cells, rather than the proteins themselves. Another drug, tepoxalin — the osteoarthritis drug for dogs — was found to target some unknown feature of cells that overexpressed the protein MDR1 (a protein that provides cancerous cells with resistance to chemotherapy drugs), providing a subject for future study.

Other drugs were discovered to kill cells based on their expression of biomarkers, meaning that the patients who would benefit the most from those drugs could be quickly identified. Disulfiram, the alcohol dependence drug, was found to kill cells with low expressions of metallothionein proteins, for example. Vanadium, the diabetes drug, killed cells expressing a certain sulfate transporter protein. By looking for low levels of metallothionein or high levels of this sulfate transporter, doctors can quickly assess whether a patient will respond well to treatment using these drugs.

The Broad Institute's Repurposing Hub is growing rapidly, containing thousands of more compounds now than when this study was initially carried out. Not only does work like this identify useful drugs and future subjects of research, but it also acts as proof that many other compounds out there have useful applications in treating conditions other than those they were designed for. This study focused on treating cancer, but any number of alternative conditions could be the focus of future research. It could be the case that the answers to many of our problems are sitting right under our noses.

LIVE EVENT | Radical innovation: Unlocking the future of human invention

Innovation in manufacturing has crawled since the 1950s. That's about to speed up.

Big Think LIVE

Add event to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo

Keep reading Show less

Two MIT students just solved Richard Feynman’s famed physics puzzle

Richard Feynman once asked a silly question. Two MIT students just answered it.

Surprising Science

Here's a fun experiment to try. Go to your pantry and see if you have a box of spaghetti. If you do, take out a noodle. Grab both ends of it and bend it until it breaks in half. How many pieces did it break into? If you got two large pieces and at least one small piece you're not alone.

Keep reading Show less

Unfiltered lessons of a female entrepreneur

Join Pulitzer Prize-winning reporter and best-selling author Charles Duhigg as he interviews Victoria Montgomery Brown, co-founder and CEO of Big Think.

Big Think LIVE

Women today are founding more businesses than ever. In 2018, they made up 40% of new entrepreneurs, yet in that same year, they received just 2.2% of all venture capital investment. The playing field is off-balance. So what can women do?

Keep reading Show less

Why ‘Christian nationalists’ are less likely to wear masks and social distance

In a recent study, researchers examined how Christian nationalism is affecting the U.S. response to the COVID-19 pandemic.

A Catholic priest wearing a facemask and face shield blesses a hospital on August 6, 2020 in Manila, Philippines

Ezra Acayan/Getty Images
  • A new study used survey data to examine the interplay between Christian nationalism and incautious behaviors during the COVID-19 pandemic.
  • The researchers defined Christian nationalism as "an ideology that idealizes and advocates a fusion of American civic life with a particular type of Christian identity and culture."
  • The results showed that Christian nationalism was the leading predictor that Americans engaged in incautious behavior.
Keep reading Show less
Sex & Relationships

Two-thirds of parents say technology makes parenting harder

Parental anxieties stem from the complex relationship between technology, child development, and the internet's trove of unseemly content.

Scroll down to load more…